Literature DB >> 28002207

Correspondence: Premature Stop of the SOCceR Trial, a Multicenter Randomized Controlled Trial on Secondary Cytoreductive Surgery: Netherlands Trial Register Number: NTR3337.

Rafli van de Laar1, Roy F P M Kruitwagen, Petra L M Zusterzeel, Toon Van Gorp, Leon F A G Massuger.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28002207     DOI： 10.1097/IGC.0000000000000841

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   3.437


× No keyword cloud information.
  4 in total

1.  Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer.

Authors:  Giorgio Bogani; Diego Rossetti; Antonino Ditto; Fabio Martinelli; Valentina Chiappa; Lavinia Mosca; Umberto Leone Roberti Maggiore; Stefano Ferla; Domenica Lorusso; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2018-04-23       Impact factor: 4.401

2.  Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?

Authors:  Rongyu Zang; Jianqing Zhu
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

3.  The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.

Authors:  Ting Ding; Dan Tang; Mingrong Xi
Journal:  J Ovarian Res       Date:  2021-07-13       Impact factor: 4.234

4.  The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial.

Authors:  Hongyuan Gu; Rui Zhou; Jing Ni; Xia Xu; Xianzhong Cheng; Yan Li; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2020-06-16       Impact factor: 4.234
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.